• Hello, please SIGN-UP FOR A FREE account and become a member of our community!
    You will then be able to start threads, post comments and send messages to other members. Thanks!
  • 💪IronMag Labs® 30% Off Easter Sale👉www.ironmaglabs.com Coupon code: EASTER30🐰

OSTA Rx™ - SARM

heavyiron

Administrator
Joined
Aug 10, 2011
Messages
3,607
Reaction score
42
Points
0
Location
Staying Anabolic
OSTA Rx™ - SARM

Selective Androgen Receptor Modulator (SARM)

attachment.php


-Non-hormonal Anabolic Compound
-Increases Lean Muscle Mass
-Promotes Fat Loss
-Promotes Recovery
-Increases Libido
-Safe for Males & Females
-Can be used for PCT and Bridging


(MK-2866) ~ ((2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)


Osta Rx™ is a Selective Androgen Receptor Modulator. A SARM is exactly what it sounds like: a compound (not an anabolic steroid) which has the ability to stimulate the androgen receptor (much the same way as anabolic steroids). Osta Rx™ is an orally active (and highly bioavailable) selective agonist for androgen receptors which was shown to have anabolic effects in muscle and bone tissue. It has been shown to have no measurable effect on lutenizing hormone (LH) or follicle-stimulating hormone (FSH), but it has been shown to have some effect on prostate weight, with an androgenic potency around 1/3rd of its anabolic potency. Still, this is a good trade-off, because it’s anabolic effect has been measured to be roughly the same as testosterone. It has also been shown to produce dose-dependent increases in bone mineral density and mechanical strength in addition to being able decrease body fat and
increase lean body mass.

Selective androgen receptor modulators (SARMs) bind to the androgen receptor and demonstrate osteo (bone) and myo (muscular) anabolic activity. Binding and activation of the Androgen receptor alters the expression of genes and increases protein synthesis, hence builds muscle. So in essence, SARMs such as Osta Rx™ causes muscle growth in the same manner as steroids, however unlike testosterone and other anabolic steroids and prohormones, SARMs (as nonsteroidal agents) don’t produce the growth effect on prostate and other secondary sexual organs.

Osta Rx™ in particular exerts its anabolic effects on muscle tissue almost exclusively. So not only does it represent a new potential treatment option for a wide spectrum of conditions from muscle wasting diseases (from age-related to AIDS or cancer-related), but is also has immense potential for muscle building for Bodybuilders, fitness, athletes and an agent to minimize atrophy during recovery periods from serious surgery or similar situations.

Support Ingredients in Osta Rx™

Mucuna Pruriens ~ contains a very powerful neurotransmitter pre-cursor L-Dopa. Mucuna pruriens is a reputed remedy of Ayurveda in nervous and sexual diseases. Traditionally, Mucuna pruriens is commonly used as carminative, hypertensive and hypoglycemic agent. Mucuna pruriens has been found to contain L-DOPA, 40 mg/g of the plant. The plant/seeds contain the bioactive alkaloids mucunine, mucunadine, mucuadinine, pruriendine and nicotine, besides B-sitosterol, glutathione, lecithin, oils, venolic and gallic acids. Studies in experimental model show L-Dopa also helps in the reduction of cholesterol and blood sugar levels.

L-Dopa is an amino acid that converts into dopamine. Dopamine is an essential component of our body and it's required for proper functioning of the brain. Research discovered the body converts the amino acid tyrosine into L-dopa; L-dopa is then converted into dopamine. Without the neurotransmitter dopamine to serve a damping effect on neural transmissions, muscles become tense and tremble.

Benefits of Mucuna Pruriens L-Dopa:

-Improved sleep (promotes deep sleep)
-Reduced bodyfat & decreased cellulite
-Improved skin texture & appearance
-Increased bone density and reversal of osteoporosis
-Increased lean muscle mass
-Improved mood and sense of well-being
-Enhanced libido & sexual performance
-Increased energy levels
-Improved cholestorol profile & regeneration of organs (heart, kidney, liver, lungs)
-Dramatically strengthens immune system

Mucuna: Human Growth Hormone


L- Dopa contains natural secretagogues which may support the body's ability to stimulate the natural release of growth hormone. The blood carries the dopamine into the brain, where it naturally increases HGH production from the pituitary gland. The increased dopamine levels also optimize the production of other hormones, including testosterone, leading to increased sex drive and improved sexual performance for both men and women, beneficial in stimulating muscle growth, as well as burning fat from fat cells.

Fenuside ~ is a testosterone booster containing Fenuside saponins, extracted from the herb Fenugreek (Trigonella foenum-graecum). Fenuside is designed to boost testosterone levels, muscle size and sex drive, and is considered one of the very latest testosterone boosters in the sports supplement market. It is important to note that there are over 100 natural chemicals in Fenugreek, but it's only standardised Fenuside saponins that are proven to offer bodybuilders, gym users and athletes beneficial effects on muscle size, testosterone levels and body composition.

The fenuside saponins found in Fenuside are designed to support hormone levels and act as a powerful but safe testosterone booster in individuals desiring fast and noticeable enhancements in muscle size, strength and performance. The supplement is useful for strength and power athletes, body builders, and serious gym users.

Research suggests that Fenuside mechanism of action is initially as an adrenal cortex stimulator, subsequently activating the hypothalamus and boosting natural production of corticotropin releasing hormone (CRH). CRH switches on the powerful pituitary gland, enhancing production of the key adrenocorticotrophin hormone (ACTH). ACTH is a potent stimulant on the adrenal cortex to increase androgen synthesis. Because androgens are precursors to Testosterone and possess "Testosterone like activity", Testofen naturally supports the activity of the luteinizing hormone, acting as a testosterone booster.

Horny Goat Weed ~ Icariin is the active element of Epimedium Extract (also commonly known as Horny Goat Weed Extract) and this ingredient when extracted to high purity's is an exceptionally powerful nitric oxide and testosterone booster. Icariin is a very fine grade of extract and boasts quality's which simply can't be obtained from the lower grade's of Epimedium Extract. The increased blood flow and oxygen to the muscles obtained from Icariin of this quality feeds the body with the energy and the drive required to perform and out-perform when under activities of physical and mental endurance.
 

Attachments

  • Osta.jpg
    Osta.jpg
    205.2 KB · Views: 465
Good shit Heavy!!! I recieved mine yesterday, can't wait to give it a ride.
 
how effective will osta-rx be taken orally?
 
So Heavy, whats the best way of taking these???
 
Some history and performance data;


GTx, Inc. Announces Positive Clinical Results and Development Plans for Ostarine

PRNewswire-FirstCall
Sept. 7 05

GTx, The Men's Health Biotech Company, announced today that results from its Phase I clinical trials for ostarine, its second selective androgen receptor modulator (SARM), were consistent with anabolic activity without evidence of unwanted androgenic side effects on prostate and skin sebaceous glands. GTx intends to begin a Phase II clinical trial of ostarine for the treatment of muscle wasting associated with burns during the fourth quarter of 2005.

"We are excited with the outcome of our Phase I clinical trials of ostarine. Now that ostarine is poised to enter Phase II clinical trials, it becomes our lead SARM compound," said Mitchell Steiner, MD, chief executive officer of GTx.

"Results from our recently completed multiple-ascending dose clinical trial have allowed us to pick doses of ostarine to advance into Phase II clinical trials. We have also zeroed in on developing ostarine for muscle wasting associated with an acute condition, burns, for which we believe ostarine fills an unmet medical need and which may provide us with an efficient path to market.

We remain excited by other, broader market possibilities for ostarine, such as muscle wasting associated with andropause, and we intend to initiate a second Phase II clinical trial of ostarine for this indication in the first half of 2006."

About Ostarine

Ostarine is a non-steroidal, oral SARM, all rights to which are held by GTx. GTx believes that ostarine has the potential to treat muscle wasting associated with chronic conditions, such as end-stage renal disease, frailty and andropause, as well as muscle wasting associated with acute conditions, such as burns.

Ostarine is the second SARM that GTx has brought from discovery into clinical trials. GTx also discovered andarine, a SARM that GTx and its collaborator, Johnson & Johnson's subsidiary, Ortho Biotech Products L.P., are developing to treat cancer cachexia.

Planned Phase II Clinical Trials for Ostarine

GTx plans to initiate Phase II clinical trials of ostarine first for muscle wasting associated with burns because acute indications have a relatively expeditious and defined clinical development and regulatory pathway. Burn patients are hypermetabolic and lose significant lean body weight, which adversely affects their healing and recovery.

GTx expects to begin its Phase II clinical trial of ostarine for muscle wasting associated with burns in the fourth quarter of 2005. Studies have already established proof-of-concept for the use of anabolic agents in the treatment of burns. Because ostarine has a long half life (24 hours) and provides levels of circulating androgens unattainable with anabolic steroidal agents, GTx believes that this selective, potent, non-steroidal anabolic agent would be an important step forward in the treatment of burn patients.

"We believe that the treatment of burn patients represents an excellent first path for GTx to pursue for ostarine," said Dr. Steiner. "A powerful anabolic agent without unwanted steroidal side effects could help speed the recovery of burn victims. For GTx, the treatment of burn patients offers a relatively expeditious route to market for its lead SARM."

GTx plans to continue clinical development of ostarine for chronic muscle wasting due to low testosterone in aging men (a condition also known as andropause). Between 30 and 60 years of age, men on average gain a pound of fat and lose a half pound of muscle, and muscle loss accelerates after age 60. This loss of muscle mass can lead to frailty and loss of independence. GTx plans to initiate Phase II clinical testing for the treatment of andropause during the first half of 2006.

About Ostarine's Phase I Multiple Ascending Dose Clinical Trial Results

The Phase I multiple-ascending dose clinical trial evaluated the safety, tolerability and specific pharmacodynamic characteristics of ostarine in a double-blind, placebo-controlled study in 48 healthy male volunteers, 18-45 years of age, and 12 elderly males with truncal obesity, who averaged 68 years of age.

Safety and pharmacodynamic measurements were taken at the beginning of the study and after 14 days of daily oral dosing. These measurements included routine blood chemistry and hematology, sex hormones and gonadotropins, serum prostate specific antigen, metabolic markers of bone and muscle, cutaneous sebum analysis and DEXA scanning for body composition.

Ostarine is designed to have anabolic building activity without unwanted androgenic side effects on prostate and skin sebaceous glands. Overall, clinical laboratory values and hormonal effects determined from the study were consistent with anabolic activity. Comparisons of DEXA assessments from the beginning of the study to DEXA assessments after 14 days showed positive changes in body composition, with lean body mass and fat mass in study patients moving in a direction consistent with anabolic activity.

Based on other tests, ostarine did not appear to have unwanted side effects on the prostate or the skin. GTx believes that these observations support the potential ability of ostarine to selectively modulate androgen receptors in a tissue-specific manner.

There were no drug-related serious adverse events related to ostarine in the clinical trial. Doses that were found to be safe in this study were selected to enter Phase II testing later this year.

About GTx

GTx is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics for cancer and serious conditions related to men's health. GTx's lead drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens, two essential classes of hormones.

GTx, headquartered in Memphis, Tenn., currently has four clinical programs.

GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: (1) a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer and (2) a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with precancerous prostate lesions.

In its third clinical program, GTx is developing ostarine for the treatment of muscle wasting associated with acute conditions such as burns and chronic conditions such as andropause. GTx expects to begin Phase II clinical trials of ostarine for muscle wasting associated with burns in the fourth quarter of 2005 and for andropause during the first half of 2006.

In its fourth clinical program, GTx and its collaborator, Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson, are developing andarine, another one of GTx's SARMs, for the treatment of cancer cachexia. GTx is working with Ortho Biotech to plan a Phase II clinical trial of andarine.
 
GTX Inc. Starts Ostarine Mid-Stage Trial

AP
May 15, 2006
Chron.com

MEMPHIS, Tenn. ? Biotech company GTX Zoek Inc. said Monday it has initiated a mid-stage trial of ostarine Zoek for the treatment of osteoporosis.

Neo-androgeen

The trial will evaluate the drug's safety and its ability to build muscle and promote bone in 120 elderly men and postmenopausal women.

Ostarine, a first-in-class drug, is a selective androgen receptor modulator, or SARM. Zoek In preclinical trials, ostarine distinguished itself from current osteoporosis drugs which only treat bone loss by also increasing muscle.

Mitchell S. Steiner, Zoek chief executive of GTX, said "The clinical data will determine ostarine's novel anabolic effects and tissue selectivity. These data will support further development of ostarine for acute muscle-wasting indications such as cancer, end-stage renal disease, or burn-injury wasting conditions, and for chronic indications such as osteoporosis and age-related frailty."

The company, which has all rights to ostarine, expects to report clinical data in the second half of the year.

GTX develops therapeutics for cancer and serious conditions related to men's health. Shares rose 65 cents, or 7.6 percent, to $9.20 on the Nasdaq.
 
GTx Announces That Ostarine Achieved Primary Endpoint Of Lean Body Mass And A Secondary Endpoint Of Improved Functional Performance

GTx, Inc.
09 Dec 2006

GTX, the Men's Health Biotech Company, today announced that ostarine, a first-in-class selective androgen receptor modulator (SARM), met its primary endpoint in a Phase II proof of concept double blind, randomized, placebo controlled clinical trial in 120 subjects (60 elderly men and 60 postmenopausal women).

Without a prescribed diet or exercise regimen, all subjects treated with ostarine had a dose dependent increase in total lean body mass (muscle), with the 3 mg cohort achieving an increase of 1.3 kg compared to baseline and 1.4 kg compared to placebo (p<0.001) after three months of treatment.

Treatment with ostarine also resulted in a dose dependent improvement in functional performance measured by a stair climb test, with the 3 mg cohort achieving a clinically significant improvement in both speed (p=0.006) and power (p=0.005).

Ostarine continued to demonstrate a favorable safety profile, with no serious adverse events reported. Ostarine also exhibited tissue selectivity with beneficial effects on lean body mass and performance and with no apparent change in measurements for serum PSA (prostate), sebum production (skin and hair), or serum LH (pituitary) compared to placebo.

The Phase II clinical trial evaluated four doses of ostarine (0.1 mg, 0.3 mg, 1 mg, and 3 mg) versus placebo for three months in 60 elderly men (average age 66 years) and 60 postmenopausal women (average age 63 years). The trial was conducted in five clinical sites in the United Kingdom and Germany.

A summary of the topline data is as follows:

-- Among females (n=56), ostarine treatment resulted in a dose dependent increase in LBM with the 3 mg dose having an increase of 1.7 kg compared to baseline and an increase of 1.4 kg compared to placebo (p=0.02).

-- Among males (n=58), treatment with a 1 mg dose of ostarine resulted in a LBM increase of 0.7 kg compared to baseline and an increase of 1.2 kg compared to placebo (p=0.03), and treatment with a 3 mg dose of ostarine resulted in an increase of 1.0 kg compared to baseline and an increase of 1.4 kg compared to placebo (p=0.005).

-- Total tissue percent fat decreased compared to placebo in a dose dependent fashion and achieved statistical significance at the 1 mg dose (p=0.02) and 3 mg dose (p=0.006) of ostarine.

Total fat mass was lower in subjects receiving either the 3 mg or 1 mg ostarine dose, although not at a statistically significant level (p = 0.08 for both doses). For subjects receiving the 3 mg ostarine dose, total fat on average declined 0.6 kg compared to placebo.

The site of fat loss differed among male and female subjects, with males losing fat primarily from the trunk and abdomen, and females losing fat primarily from the thighs and legs.

-- In this short trial, ostarine had no apparent effect on bone mineral density, and bone turnover markers results were mixed. In preclinical in vitro and in vivo models, ostarine demonstrated both anabolic and antiresorptive activity on bone. A longer clinical study is necessary to demonstrate the actual effects of ostarine on bone.

-- Ostarine continued to demonstrate a favorable safety profile, with no serious adverse events reported.

-- At the end of three months, no subject had clinically meaningful levels in liver enzyme tests. However, one female discontinued the study per protocol due to elevated liver enzymes which returned to baseline.

-- Ostarine treatment resulted in a dose dependent decrease in both LDL and HDL cholesterol levels, with the average LDL/HDL ratio for all doses tested remaining in the low cardiovascular risk category.

-- Ostarine treatment resulted in no apparent effect on serum PSA (prostate), sebum production (skin and hair), or serum LH (pituitary).
 
*Now 25% Off!

OSTA Rx™ - SARM

Selective Androgen Receptor Modulator (SARM)

*Now 25% Off!

Osta Rx is a one of a kind product, there are NO other supplement companies with this type of formula on the market!

25% Off Coupon Code = OSTA25 (enter in shopping cart).
 
Can I start osta rx by itself, after I completed my halo extreme stack? With osta, I don't need to run any pct cycle rite? Thanks
 
Can I start osta rx by itself, after I completed my halo extreme stack? With osta, I don't need to run any pct cycle rite? Thanks

It depends how u wanna run Osta. U can run it with PCT (my suggestion) so your more likely to keep your gains and help with strength during pct. And no u dont need to run a PCT for osta.
 
It depends how u wanna run Osta. U can run it with PCT (my suggestion) so your more likely to keep your gains and help with strength during pct. And no u dont need to run a PCT for osta.

Agreed. I like to add Osta in the last two weeks into pct and run for a total for 8wks in preparation for another PH cycle run
 
J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):153-161. Epub 2011 Aug 2.

The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.

Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS.

Source
GTx, Inc., 175 Toyota Plaza, Memphis, TN 38103 USA.

Abstract

BACKGROUND:

Cachexia, also known as muscle wasting, is a complex metabolic condition characterized by loss of skeletal muscle and a decline in physical function. Muscle wasting is associated with cancer, sarcopenia, chronic obstructive pulmonary disease, end-stage renal disease, and other chronic conditions and results in significant morbidity and mortality. GTx-024 (enobosarm) is a nonsteroidal selective androgen receptor modulator (SARM) that has tissue-selective anabolic effects in muscle and bone, while sparing other androgenic tissue related to hair growth in women and prostate effects in men. GTx-024 has demonstrated promising pharmacologic effects in preclinical studies and favorable safety and pharmacokinetic profiles in phase I investigation.

METHODS:

A 12-week double-blind, placebo-controlled phase II clinical trial was conducted to evaluate GTx-024 in 120 healthy elderly men (>60 years of age) and postmenopausal women. The primary endpoint was total lean body mass assessed by dual energy X-ray absorptiometry, and secondary endpoints included physical function, body weight, insulin resistance, and safety.

RESULTS:

GTx-024 treatment resulted in dose-dependent increases in total lean body mass that were statistically significant (P < 0.001, 3 mg vs. placebo) and clinically meaningful. There were also significant improvements in physical function (P = 0.013, 3 mg vs. placebo) and insulin resistance (P = 0.013, 3 mg vs. placebo). The incidence of adverse events was similar between treatment groups.

CONCLUSION:

GTx-024 showed a dose-dependent improvement in total lean body mass and physical function and was well tolerated. GTx-024 may be useful in the prevention and/or treatment of muscle wasting associated with cancer and other chronic diseases.

PMID: 22031847 [PubMed] PMCID: PMC3177038

http://www.ncbi.nlm.nih.gov/pubmed/22031847
 
Just ordered a bottle of this today, hoping to run for about 4-5 weeks then start cycle of halo, excited to see what these SARMS are all about and if the hype is real.
 
Just ordered a bottle of this today, hoping to run for about 4-5 weeks then start cycle of halo, excited to see what these SARMS are all about and if the hype is real.
I'm 5wks into Osta.. it's real. ;)
 
2.5 weeks into my Halo/Cyano PCT. Just ordered a bottle of Osta. Thinking about adding it in soon to keep the gains going before my DMZ bulk in a couple months.
 
2.5 weeks into my Halo/Cyano PCT. Just ordered a bottle of Osta. Thinking about adding it in soon to keep the gains going before my DMZ bulk in a couple months.
Go for it, man! You're gonna love the vascularity from it!
 
Go for it, man! You're gonna love the vascularity from it!

You were right bro... 9 days into this at 3 caps a day and I'm loving it. Up 3lbs already, getting vascular again, and my drive is through the roof. I'm gonna run this for 8 weeks then take two weeks off before my DMZ 2.0 bulk.
 
You were right bro... 9 days into this at 3 caps a day and I'm loving it. Up 3lbs already, getting vascular again, and my drive is through the roof. I'm gonna run this for 8 weeks then take two weeks off before my DMZ 2.0 bulk.
:cool:
 
Curious as to how many mg's of Ostarine are in each capsule?
 
I've never purchased anything form ironmaglabs before so I'm kind of weary of making such a big purchase. Can you guarantee me that OSTA Rx legitimately has Ostarine in it? I know there are many Research Chemical companies out there selling PH's and other knock off's and claiming it is Ostarine.
 
I've never purchased anything form ironmaglabs before so I'm kind of weary of making such a big purchase. Can you guarantee me that OSTA Rx legitimately has Ostarine in it? I know there are many Research Chemical companies out there selling PH's and other knock off's and claiming it is Ostarine.

Yes.
 
I've never purchased anything form ironmaglabs before so I'm kind of weary of making such a big purchase. Can you guarantee me that OSTA Rx legitimately has Ostarine in it? I know there are many Research Chemical companies out there selling PH's and other knock off's and claiming it is Ostarine.
It's legitimate... I'm heading into my 3rd and final month of Osta. Excellent stuff.
 
Back
Top